Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · IEX Real-Time Price · USD
-0.020 (-1.92%)
At close: Jul 17, 2024, 4:00 PM
-0.020 (-1.96%)
After-hours: Jul 17, 2024, 7:57 PM EDT

Company Description

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.

The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.

It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome.

The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics Inc.
Ovid Therapeutics logo
Country United States
Founded 2014
IPO Date May 5, 2017
Industry Biotechnology
Sector Healthcare
Employees 40
CEO Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir

Contact Details

441 Ninth Avenue, 14th Floor
New York, New York 10001
United States
Phone 212-776-4381
Website ovidrx.com

Stock Details

Ticker Symbol OVID
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001636651
CUSIP Number 690469101
ISIN Number US6904691010
Employer ID 46-5270895
SIC Code 2834

Key Executives

Name Position
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir President, Chief Executive Officer and Chairman
Jeffrey A. Rona Principal Financial Officer, Principal Accounting Officer and Chief Business and Financial Officer
Jason Tardio M.B.A. Chief Operating Officer
Lora Pike Senior Director of Investor Relations and Public Relations
Thomas Michael Perone J.D., M.B.A. General Counsel
Simon D. Kelner Chief Human Resources Officer
Dr. Dirk Haasner Senior Vice President of Global Manufacturing and CMC QA
Dr. Todd F. Baumgartner M.D., M.P.H. Senior Vice President of Regulatory Affairs
Dr. Julia Tsai Ph.D. Senior Vice President of Clinical Development
Meg Alexander Chief Strategy Officer

Latest SEC Filings

Date Type Title
Jul 1, 2024 8-K Current Report
Jun 28, 2024 8-K Current Report
Jun 17, 2024 8-K Current Report
Jun 7, 2024 8-K Current Report
May 14, 2024 S-8 Securities to be offered to employees in employee benefit plans
May 14, 2024 10-Q Quarterly Report
May 14, 2024 8-K Current Report
Apr 24, 2024 ARS Filing
Apr 24, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2024 DEF 14A Other definitive proxy statements